Novanta Inc.
NASDAQ•NOVT
CEO: Mr. Matthijs Glastra
板块: Technology
行业: Hardware, Equipment & Parts
上市日期: 1999-03-24
Novanta Inc., together with its subsidiaries, provides precision medicine and manufacturing, medical solutions, and robotics and automation solutions in the United States and internationally. The company operates through three segments: Precision Medicine and Manufacturing, Medical Solutions, and Robotics and Automation. The Precision Medicine and Manufacturing segment offers photonics-based solutions, including laser scanning, beam delivery, CO2 laser, solid state laser, ultrafast laser, and optical light engine products serving photonics-based applications for industrial processing, metrology, medical and life science imaging, DNA sequencing, and medical laser procedures. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; wireless technologies, video recorders, and video integration technologies for operating room integrations; optical data collection and machine vision technologies; radio frequency identification technologies; thermal chart recorders; spectrometry technologies; and embedded touch screen solutions. The Robotics and Automation segment offers optical and inductive encoders, precision motors, servo drives and motion control solutions, integrated stepper motors, intelligent robotic end-of-arm technology solutions, air bearings, and air bearing spindles. The company sells its products through its direct sales force and distributors under the Cambridge Technology, Synrad, Laser Quantum, ARGES, WOM, NDS, Med X Change, Reach Technology, JADAK, ThingMagic, Photo Research, General Scanning, ATI Industrial Automation, Celera Motion, IMS, MicroE, Applimotion, Zettlex, Ingenia, and Westwind brands. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is headquartered in Bedford, Massachusetts.
联系方式
市值
$4.17B
市盈率 (TTM)
82.9
21.9
股息率
--
52周最高
$149.95
52周最低
$98.27
52周范围
排名40Top 42.0%
4.1
F-Score
改良版 Piotroski 分析
基于 10 年期基本面
一般 • 4.1 / 9 分
评分区间 (0-9)
8-9: 价值优异
6-7: 基本面强劲
4-5: 整体稳健
0-3: 表现疲弱
数据范围: 2016-2025
财务仪表盘
Q4 2025 数据
营业收入
$258.35M+0.00%
近4季度走势
每股收益
$0.46+0.00%
近4季度走势
自由现金流
$5.13M+0.00%
近4季度走势
2025 Annual 财报亮点
核心亮点
Revenue Growth Strong Total revenue reached $980.6M, marking a 3.3% increase; Medical Solutions revenue grew 4.6% to $479.8M.
Major Equity Financing Closed Issued 6.50% tangible equity units, securing $613.1M net proceeds in November 2025 to bolster liquidity position.
Backlog Signals Future Demand Consolidated backlog increased to $481.2M as of year-end 2025, up from $445.5M in 2024, indicating order strength.
Automation Revenue Rises Automation Enabling Technologies segment revenue increased 2.1% to $500.8M, driven by robotics and automation product sales.
关注风险
Operating Income Declined Operating income fell 15.0% to $94.0M in 2025, driven by higher SG&A and restructuring/acquisition related costs.
Customer Concentration Exposure Top two OEM customers represented 23% of 2025 consolidated revenue, posing concentration risk if orders significantly reduce.
Regulatory Complexity High Subject to extensive and dynamic medical device regulations across US, EU, and UK, increasing compliance complexity and costs.
Margin Pressure Evident Automation segment gross margin slightly decreased due to higher tariff costs and temporary increases from regional manufacturing strategy.
前瞻展望
Medical Sales Mix Focus Strategy centers on improving business mix to increase medical sales percentage of total revenue via new product introductions.
Capital Structure Management Debt level stands at $259.6M total; $850.0M unused borrowing capacity available under the revolving credit facility.
Operational Efficiency Improvement Plans include strengthening operational performance via lean manufacturing and advancing strategic sourcing initiatives across major sites.
Technology Acquisition Strategy Will continue broadening portfolio through investment in new product development and pursuing complementary medical technology acquisitions.
同行对比
营业收入 (TTM)
$4.13B
$3.71B
$3.08B
毛利率 (最新季度)
102.1%
65.5%
58.7%
关键指标
股票代码 | 市值 | 市盈率 (TTM) | 净资产收益率 (TTM) | 负债率 |
|---|---|---|---|---|
| VICR | $7.77B | 65.8 | 18.7% | 1.6% |
| ESE | $6.83B | 22.4 | 21.3% | 7.9% |
| DOCN | $6.31B | 24.2 | -214.1% | 39.8% |
长期趋势
近4季度
营业收入
净利润
经营现金流
4季度营收复合增长率
3.4%
温和增长
4季度净利润复合增长率
-6.3%
盈利能力下滑
现金流稳定性
100%
现金流表现优异
深度研究
下次财报:2026年5月4日
每股收益:-
|营业收入:-
财务数据
电话会议
财务报告
新闻
利润表
资产负债表
现金流量表
财务比率
变化率
利润表 | 过去12个月 |
|---|
无数据